Your browser doesn't support javascript.
loading
HMGB1 and RAGE in inflammation and cancer.
Sims, Gary P; Rowe, Daniel C; Rietdijk, Svend T; Herbst, Ronald; Coyle, Anthony J.
Afiliação
  • Sims GP; Department of Respiratory, Inflammation and Autoimmune Disease, MedImmune, Gaithersburg, Maryland 20878, USA.
Annu Rev Immunol ; 28: 367-88, 2010.
Article em En | MEDLINE | ID: mdl-20192808
The immune system has evolved to respond not only to pathogens, but also to signals released from dying cells. Cell death through necrosis induces inflammation, whereas apoptotic cell death provides an important signal for tolerance induction. High mobility group box 1 (HMGB1) is a DNA-binding nuclear protein, released actively following cytokine stimulation as well as passively during cell death; it is the prototypic damage-associated molecular pattern (DAMP) molecule and has been implicated in several inflammatory disorders. HMGB1 can associate with other molecules, including TLR ligands and cytokines, and activates cells through the differential engagement of multiple surface receptors including TLR2, TLR4, and RAGE. RAGE is a multiligand receptor that binds structurally diverse molecules, including not only HMGB1, but also S100 family members and amyloid-beta. RAGE activation has been implicated in sterile inflammation as well as in cancer, diabetes, and Alzheimer's disease. While HMGB1 through interactions with TLRs may also be important, this review focuses on the role of the HMGB1-RAGE axis in inflammation and cancer.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores Imunológicos / Proteína HMGB1 / Inflamação / Neoplasias Limite: Animals / Humans Idioma: En Revista: Annu Rev Immunol Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores Imunológicos / Proteína HMGB1 / Inflamação / Neoplasias Limite: Animals / Humans Idioma: En Revista: Annu Rev Immunol Ano de publicação: 2010 Tipo de documento: Article País de afiliação: Estados Unidos